ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Concepts for New, Recompeted DCCP Contracts Approved

June 12, 1981

Also NCI prostate SPOREs plan biospecimen bank.

December 10, 2004

DCE Recompetition Of Human Tissue Procurement Approved

November 23, 1990

Patient Harm—Including One Death—Cited As Faculty Challenges MD Anderson Leadership

September 20, 2013

NSABP Operations Office Moves Across Town To Allegheny

December 13, 1996

New: Special Reports on the Dialogue and NCI’s 2015 goal posted at cancerletter.com.

August 8, 2003